| scholarly article | Q13442814 |
| P2093 | author name string | R W Jelliffe | |
| B J Shapiro | |||
| A A Vinks | |||
| P M Beringer | |||
| P2860 | cites work | Should clearance be normalised to body surface or to lean body mass? | Q34448552 |
| Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis | Q35259780 | ||
| Killing and regrowth of bacteria in vitro: a review. | Q37803210 | ||
| Duration and clinical relevance of postantibiotic effect in relation to the dosing interval | Q39557342 | ||
| Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance | Q39673276 | ||
| Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro | Q39778914 | ||
| Single daily dosing of aminoglycosides. | Q40477943 | ||
| The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents | Q40517235 | ||
| Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions. | Q40829169 | ||
| Exploration of once-daily dosing of aminoglycosides through Bayesian simulation. | Q40947597 | ||
| Management of pulmonary disease in patients with cystic fibrosis | Q41002731 | ||
| Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models | Q42169493 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm | Q44648863 | ||
| Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia | Q46611376 | ||
| Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin | Q46984010 | ||
| A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. | Q53971692 | ||
| Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 | ||
| Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia | Q54608322 | ||
| Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone | Q67285211 | ||
| Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis | Q67999563 | ||
| Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum | Q69967341 | ||
| Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 | ||
| Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum | Q70459430 | ||
| Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation | Q71703068 | ||
| Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients | Q71765938 | ||
| Cystic fibrosis | Q71767385 | ||
| Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro | Q72196470 | ||
| Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients | Q73208219 | ||
| Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis | Q73875990 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cystic fibrosis | Q178194 | ||
| P304 | page(s) | 809-813 | |
| P577 | publication date | 2000-04-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration | |
| P478 | volume | 44 |
| Q39097052 | Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis |
| Q38823748 | Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis |
| Q44746169 | Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation |
| Q36191093 | Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis |
| Q55015958 | Extended Interval Tobramycin Pharmacokinetics in a Pediatric Patient With Primary Ciliary Dyskinesia Presenting With an Acute Respiratory Exacerbation. |
| Q37661512 | Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis |
| Q42017846 | In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis |
| Q37149666 | Intensive care management of the patient with cystic fibrosis |
| Q63346417 | Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice? |
| Q38051316 | Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature |
| Q35738386 | Once-daily aminoglycoside dosing: An update on current literature |
| Q38133781 | Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides. |
| Q35557791 | Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q51933433 | Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q36911111 | Pharmacokinetics and pharmacodynamics of antibacterial agents |
| Q37263821 | Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation |
| Q45019997 | Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis |
| Q37940005 | Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis |
| Q43276198 | Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients |
| Q37608274 | Update on antibiotics for infection control in cystic fibrosis |
Search more.